Skip to Content
COVID-19 Resources
Contact DCTD
Show menu
Search this site
Last Updated: 09/12/2017

NCI Awards Cancer Moonshot℠ Grants in Five Areas of Precision Medicine Oncology

With the goal of advancing health and treatments for disease through research that considers the molecular makeup of each person’s tumor, in September 2016, DCTD funded fifty-three 1-year supplements to already funded grants in six strategic areas of precision medicine oncology (PMO). Building upon these supplements, NCI’s Board of Scientific Advisors (BSA) approved five concepts in PMO in October 2016. Subsequently, Funding Opportunity Announcements (FOAs) that align with efforts of the Cancer Moonshot and relate to the following five PMO areas were released: canine immunotherapy trials, pancreatic ductal adenocarcinoma microenvironment, immunoprofiling and biomarkers, treatment resistance, and patient-derived xenograft models.

In response to these FOAs, the following Cancer Moonshot grants were funded in September 2017:

Canine Immunotherapy Trials and Correlative Studies (U01)
Coordinating Center for Canine Immunotherapy Trials and Correlative Studies (U24)

Activity Code PI(s) Grant Title Lead Institution
U01 Robert Canter (contact);
Robert Rebhun
Enhancing Natural Killer Immunotherapy with First-in-Dog Trials of Inhaled Recombinant IL-15 and Super-agonist IL-15 in Naturally Occurring Canine Cancers University of California at Davis
U01 M. R. Chambers Canine Immuno Neurotherapeutics University of Alabama at Birmingham
U01 Steven Dow (contact);
Cheryl London
Optimizing Novel Immunotherapy Combinations Targeting the Tumor Microenvironment in Canine Spontaneous Osteosarcoma Colorado State University
U01 Cheryl London (contact);
Kristy Richards
Enhancing the Efficacy of Immunotherapy in DLBCL using Rational Combination Approaches Tufts University
U01 Grace Elizabeth Pluhar Novel Combined Immunotherapeutic Strategies for Glioma: Using Pet Dogs as a Large Animal Spontaneous Model University of Minnesota
U24 Nicola Mason (contact);
Kathleen Propert
Coordinating Center for Canine Immunotherapy trials and Correlative Studies University of Pennsylvania

Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (U01)
Resource Center for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies (U24)

Activity Code PI(s) Grant Title Lead Institution
U01 Vinod Balachandran Defining Neoantigen Immunodominance for Antigen Selection and Biomarker Discovery in Human Pancreatic Cancer Immunotherapy Sloan-Kettering Institute for Cancer Research
U01 Howard Crawford Interrupting Cellular Crosstalk in the Immunosuppressive Microenvironment of Pancreas Cancer University of Michigan
U01 William Hahn Systematic Interrogation of the Pancreatic Cancer Microenvironment in Patient-Derived Specimens Dana-Farber Cancer Institute
U01 Sunil Hingorani Disrupting the Immune and Drug-Privileged Microenvironment in Pancreas Cancer Fred Hutchinson Cancer Research Center
U01 Rakesh Jain Reprogramming PDAC Tumor Microenvironment to Improve Immunotherapy Massachusetts General Hospital
U24 Ignacio Wistuba Pancreatic Ductal Adenocarcinoma Translational Resource Center (PATReC) University of Texas MD Anderson Cancer Center

Cancer Immune Monitoring and Analysis Centers (CIMACs) (U24)
Cancer Immunologic Data Common (CIDC) (U24)

Activity Code PI(s) Grant Title Lead Institution
U24 Sacha Gnjatic High-Dimensional Immune Monitoring of NCI-Supported Immunotherapy Trials Precision Immunology Institute and the Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai
U24 Holden Maecker (contact);
Sean Bendall
Immune Monitoring and Analysis of Cancer at Stanford (IMACS) Stanford Cancer Institute
U24 Ignacio Wistuba (contact);
Chantale Bernatchez;
Elizabeth Mittendorf
Translational Cancer Immune Monitoring and Analysis Center (TCIMAC) University of Texas MD Anderson Cancer Center
U24 Catherine Wu (contact);
Frank Hodi
Cancer Immune Monitoring and Analysis Center Dana-Farber Cancer Institute
U24 X. Shirley Liu (contact);
Ethan Cerami
Cancer Immunologic Data Commons Dana-Farber Cancer Institute

Mechanisms of Cancer Drug Resistance and Sensitivity (U54)

Activity Code PI(s) Grant Title Lead Institution
U54 Trever Bivona (contact);
Calvin Kuo
Bay Area Team against Resistance University of California, San Francisco
U54 Ryan Bruce Corcoran An Integrated Translational Approach to Overcome Drug Resistance Massachusetts General Hospital
U54 Charles Sawyers The MSKCC-UW Fred Hutch Prostate Cancer Drug Resistance and Sensitivity Center Memorial Sloan Kettering Cancer Center
U54 Alexander Keith Stewart Overcoming Drug Resistance in Multiple Myeloma Mayo Clinic Arizona
U54 Jeffrey Tyner (contact);
Brain Druker
Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AMIL Oregon Health & Science University

PDX Development and Trial Centers (PDTCs) (U54)
PDX Data Commons and Coordinating Center (PDCCC) for the PDX Development and Trial Centers Research Network (PDXNet) (U24)

Activity Code PI(s) Grant Title Lead Institution
U54 Ramaswamy Govindan (contact);
Shunqiang Li;
Li Ding
Washington University PDX Development and Trial Center Washington University
U54 Meenhard Herlyn Rational Approaches to Melanoma Therapy The Wistar Institute
U54 Jack Roth (contact);
Funda Meric-Bernstam
University of Texas PDX Development and Trial Center University of Texas MD Anderson Cancer Center
U54 Alana Welm (contact);
Bryan Welm;
Michael Lewis
PDX Trial Center for Breast Cancer Therapy University of Utah
U24 Jeffrey Chuang (contact);
Brandi Davis-Dusenbery
Data Coordination Center for PDX Net The Jackson Laboratory